Biologics License Application (BLA) for balstilimab submitted to FDA for patients with recurrent or metastatic cervical cancer

BLA for this anti-PD-1 antibody is for treatment of patients with disease progression on or after chemotherapy, and includes data from phase 2 single-arm trial, reporting response rates of 15% in all tumours (20% PD-L1 positive) and a median duration of response of 15.4 months.

Source:

Biospace Inc.